Viva Biotech HoldingsFRA:VB0 +2.59%47 Gross Margin % is 35.22% as of Dec. 2025, which is 14% below its 10-year median of 40.83. GuruFocus rates FRA:VB0 with a GF Score™ of 47/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 735 Biotechnology companies, Viva Biotech Holdings ranks worse than 70.88% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Viva Biotech Holdings had a gross margin of 35.22% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Viva Biotech Holdings Gross Margin % Related Terms
Viva Biotech Holdings Gross Margin % Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Viva Biotech Holdings (FRA:VB0) has a Gross Margin % of 35.22% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Viva Biotech Holdings and its competitors. This is 14% below median its historical median of 40.83. Over the past decade, Viva Biotech Holdings' Gross Margin % has ranged from 30.94 to 58.14. According to the industry distribution chart, Viva Biotech Holdings ranks #521 out of 735 companies in the Biotechnology industry, placing it in the top 70.9%.
Is Viva Biotech Holdings' Gross Margin % too high?
Viva Biotech Holdings' current Gross Margin % of 35.22% is 14% below median its 10-year median of 40.83. Over the past 10 years, this metric has ranged from a low of 30.94 to a high of 58.14. The Biotechnology industry median Gross Margin % is 60.90. Viva Biotech Holdings' value of 35.22% is 42.2% below this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #521 out of 735 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #521 out of 735 companies for Gross Margin %. This places Viva Biotech Holdings in the lower half of its industry. The industry median Gross Margin % is 60.90. Viva Biotech Holdings' value of 35.22% is 42.2% below this benchmark. Historically, Viva Biotech Holdings' own Gross Margin % has ranged from 30.94 to 58.14 over the past decade. While the company's 10-year median is 40.83 vs. the industry median of 60.90, Viva Biotech Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current Gross Margin % of 35.22% is 42.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Viva Biotech Holdings and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current Gross Margin % is 35.22%, which is 14% below median its own 10-year median of 40.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.12 — trading 48.8% above its estimated fair value. The current Gross Margin % is 35.22%, which is 14% below median its 10-year median of 40.83 and 42.2% below the Biotechnology industry median of 60.90. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Gross Margin % is 35.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.12 is trading 48.8% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Gross Margin %: 35.22% (14% below median its 10-year median of 40.83)
GF Value™: €0.08 vs. price of €0.12 (48.8% above fair value)
Industry Position: 42.2% below the Biotechnology median (#521 of 735)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score
Get the complete analysis for FRA:VB0
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
